Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

The Journal of Clinical Pharmacology ◽

10.1002/jcph.849 ◽

2016 ◽

Vol 57 (5) ◽

pp. 652-662 ◽

Author(s):

Ying Hong ◽

Vanessa Q. Passos ◽

Pai‐Hsi Huang ◽

Yvonne Y. Lau

Keyword(s):

Population Pharmacokinetics ◽

Anaplastic Lymphoma Kinase ◽

Adult Patients ◽

Anaplastic Lymphoma ◽

Genetic Abnormalities

Download Full-text

Anaplastic lymphoma kinase protein expression, genetic abnormalities, and phosphorylation in soft tissue tumors: Phosphorylation is associated with recurrent metastasis

Oncology Reports ◽

10.3892/or.2015.3806 ◽

2015 ◽

Vol 33 (4) ◽

pp. 1667-1674 ◽

Author(s):

YUKINAO ISHIBASHI ◽

HIROAKI MIYOSHI ◽

KOJI HIRAOKA ◽

FUMIKO ARAKAWA ◽

TOSHIAKI HARAGUCHI ◽

...

Keyword(s):

Soft Tissue ◽

Protein Expression ◽

Anaplastic Lymphoma Kinase ◽

Soft Tissue Tumors ◽

Anaplastic Lymphoma ◽

Genetic Abnormalities

Download Full-text

Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10

Annals of Oncology ◽

10.1093/annonc/mdw368.53 ◽

2016 ◽

Vol 27 ◽

pp. vi133 ◽

Author(s):

I. Kiss ◽

J. Rodón ◽

E. Grande Pulido ◽

S.Y. Rha ◽

S. Sathornsumetee ◽

...

Keyword(s):

Solid Tumors ◽

Anaplastic Lymphoma Kinase ◽

Hematological Malignancies ◽

Adaptive Design ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Anaplastic Lymphoma ◽

Genetic Abnormalities

Download Full-text

Regulated expression of the Anaplastic Lymphoma Kinase (ALK) in cultured rat hepatic stellate cells during transdifferentiation into myofibroblasts

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-861584 ◽

2005 ◽

Vol 43 (01) ◽

Author(s):

M Antoine ◽

CG Tag ◽

W Wirz ◽

M Mavituna ◽

AM Gressner ◽

...

Keyword(s):

Hepatic Stellate Cells ◽

Anaplastic Lymphoma Kinase ◽

Stellate Cells ◽

Anaplastic Lymphoma ◽

Regulated Expression

Download Full-text

Anaplastic Lymphoma Kinase in Human Cancer

Critical Reviews™ in Oncogenesis ◽

10.1615/critrevoncog.v17.i2.10 ◽

2012 ◽

Vol 17 (2) ◽

pp. 123-143 ◽

Author(s):

Christina Schonherr ◽

Bengt Hallberg ◽

Ruth Palmer

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Human Cancer ◽

Anaplastic Lymphoma

Download Full-text

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Line Treatment ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12593957.791402800 ◽

2012 ◽

Author(s):

Savraj Grewal

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Nutrient Restriction ◽

Organ Growth ◽

Anaplastic Lymphoma

Download Full-text

Faculty Opinions recommendation of The anaplastic lymphoma kinase in the pathogenesis of cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13353985.14725086 ◽

2011 ◽

Author(s):

Ruth Palmer

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Anaplastic Lymphoma

Download Full-text

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14822055 ◽

2012 ◽

Author(s):

John Proudfoot

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Mesenchymal Epithelial Transition Factor ◽

Factor C ◽

Mesenchymal Epithelial Transition

Download Full-text

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14323054 ◽

2011 ◽

Author(s):

John Lowe

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Mesenchymal Epithelial Transition Factor ◽

Factor C ◽

Mesenchymal Epithelial Transition

Download Full-text

Faculty Opinions recommendation of Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.716397814.793455523 ◽

2012 ◽

Author(s):

Marcio Nucci

Keyword(s):

Population Pharmacokinetics ◽

Fungal Infections ◽

Invasive Fungal Infections ◽

Adult Patients ◽

Efficacy And Safety ◽

Safety Population

Download Full-text